Systematic Review and Meta-analysis of Clinical Severity and Population-Specific Outcomes of Human Metapneumovirus Infection

Clicks: 11
ID: 331871
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #295 of 316 articles by views in Open forum infectious diseases

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 316 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Human metapneumovirus (HMPV) is a prevalent respiratory pathogen, but comprehensive estimates of severe clinical outcomes across populations are lacking, limiting evidence-based public health prioritization. We synthesized the proportion of severe outcomes among patients with laboratory-confirmed HMPV infection. Methods We searched PubMed, Embase, Web of Science, Scopus, Cochrane Library, medRxiv, bioRxiv, and Google Scholar from inception to January 20, 2026, without language restrictions. Observational studies reporting severe outcomes (hospitalization, ICU admission, respiratory support, mechanical ventilation, mortality) in laboratory-confirmed HMPV infection were eligible; studies enrolling only immunocompromised patients without comparators were excluded. Two reviewers independently extracted data and assessed quality using Joanna Briggs Institute checklists. Pooled proportions were estimated using random-effects generalized linear mixed models with logit transformation. Subgroup analyses examined healthcare setting and age. Reporting followed PRISMA guidelines. Results Ninety-four studies (∼26,000 HMPV-positive patients) were included. Pooled proportions were 48% (95% CI, 20%–78%; 8 studies, n=1,445) for hospitalization; 12% (95% CI, 8%–16%; 26 studies, n=14,522; Egger P=.03) for ICU admission; 40% (95% CI, 26%–56%; 18 studies, n=4,328) for respiratory support; 8% (95% CI, 5%–13%; 16 studies, n=5,543) for mechanical ventilation; and 3% (95% CI, 2%–5%; 29 studies, n=13,657; I2=78.5%) for in-hospital mortality. Mortality was highest among adults (6%). Sensitivity analyses excluding low-quality studies yielded consistent results. Conclusions HMPV causes substantial hospitalization, ICU admission, and mortality at rates comparable to RSV and influenza, supporting strengthened surveillance, integration into respiratory virus prevention strategies, and accelerated vaccine development.
Reference Key
openalex_W7220982093 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Yu Miao, Shangchen Song, Zachary J. Madewell, Zhumengmeng Jin, Yumiao Lei, Evelyn Shi, Yixuan Zeng, Mingjing Liu, Ira M. Longini, Yang Yang
Are you one of these authors? Claim your profile
Journal Open forum infectious diseases
Year 2026
DOI
10.1093/ofid/ofag634
URL
https://doi.org/10.1093/ofid/ofag634
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.